Wall Street Thinks Rocket Lab Is a Buy. Here's Why I'm Not So Sure.

Rocket Lab reported record quarterly revenue, up 62% year over year, and backlog exceeding $2.3 billion, but its path to profitability is deteriorating as Q2 operating expenses reached $142 million and management expects elevated cash burn for roughly two years after Neutron's first successful flight. Neutron's inaugural launch, originally targeted for 2025 and most recently guided for Q4 2026, could slip to 2027, increasing execution risk. The company is also integrating two 2026 acquisitions and preparing to close an Iridium Communications deal while trading at roughly 50x sales; shares are more than 50% below their late-May $151 peak.

Analysis

RKLB is transitioning from a high-growth space-systems story into a capital-allocation and execution test. At an ultra-premium revenue multiple, even modest schedule movement matters disproportionately: a one-year delay to Neutron shifts the point at which fixed launch infrastructure can absorb costs, extends external-financing needs, and raises the probability of dilution before operating leverage is visible. The relevant near-term KPI is not backlog alone, but backlog conversion, gross-margin progression in Space Systems, and quarterly cash use excluding acquisition-related costs.

The integration stack creates a less appreciated risk: acquired revenue can support top-line optics while obscuring whether organic margins and engineering capacity are improving. IRDM could face a near-term valuation overhang if the transaction terms imply strategic dependence on RKLB financing or execution, though a completed combination could eventually improve constellation/launch coordination and reduce third-party launch exposure. Competitors with proven heavy-lift cadence or lower financing dependence, notably SpaceX privately and defense primes LMT/NOC publicly, become relatively more attractive to risk-averse capital if RKLB's schedule confidence deteriorates.

Consensus price targets appear to embed successful Neutron execution well before the economics can be independently validated. The contrarian bull case is that a delay is already substantially discounted after the drawdown and that defense-related spacecraft demand can fund a longer runway; that requires evidence of stable burn and margin expansion over the next two earnings reports. A miss on cash-use guidance, another schedule revision, or an equity raise would likely drive further multiple compression over 1-3 months; conversely, a credible engine/vehicle milestone with unchanged liquidity assumptions is the clearest rerating catalyst.

Key Decisions for Investors

• Avoid initiating a directional RKLB long before the next earnings release; require evidence that quarterly operating cash burn is flattening and Space Systems gross margin is improving. If either deteriorates, treat it as a short/watch trigger rather than averaging down.
• For a 1-3 month bearish expression, consider RKLB put spreads rather than an outright short, sized for a schedule or financing surprise. A defined-risk structure is preferable given high short-interest/retail-driven upside risk; invalidate if management provides independently verifiable Neutron milestone progress and maintains liquidity guidance.
• Pair a small long NOC or LMT against RKLB exposure over 6-12 months for investors seeking space/defense participation with lower launch-development risk. The pair should work if procurement demand remains healthy but investors reprice RKLB's funding and schedule risk; reassess if RKLB demonstrates a credible path to launch cadence.
• Monitor IRDM deal filings for consideration, termination provisions, financing conditions, and customer-contract treatment before taking a view. Do not short IRDM solely on integration concerns; an accretive structure or strategic capacity agreement could reverse the initial overhang.